Reports

Drug name	NICE TAs	Comments
Ranibizumab injection	TA294 - Aflibercept solution for injection for treating wet age-related macular degeneration TA297 - Ocriplasmin for treating vitreomacular traction TA298 - Ranibizumab for treating choroidal neovascularisation associated with pathological myopia
Ravulizumab (Ultomiris®)	TA710 - Ravulizumab for treating atypical haemolytic uraemic syndrome TA698 - Ravulizumab for treating paroxysmal nocturnal haemoglobinuria
Regorafenib (Stivarga®)	TA488 - Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours TA514 - Regorafenib for previously treated advanced hepatocellular carcinoma TA556 - Regorafenib for previously treated advanced hepatocellular carcinoma TA866 - Regorafenib for previously treated metastatic colorectal cancer	For hospital use only
Resilizumab (Cinqaero®)	TA479 - Raslizumab for treating severe eosinophilic asthma	Hospital only
Ribociclib (Kisqali®)	TA496 - Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer TA593 - Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer TA687 - Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer	For hospital use only
Riluzole tablets	TA20 - Guidance on the use of Riluzone (Rilutek) for the treatment of Motor Neurone Disease	ESCA
Rimegepant	TA906 - Rimegepant for preventing migraine TA919 - Rimegepant for treating migraine
Risankivzub (Skyrizi®)	TA596 - Risankizumab for treating moderate to severe plaque psoriasis
Risdiplam (Evrysdi®)	TA755 - Risdiplam for treating spinal muscular atrophy
Ritlecitinib	TA958 - Ritlecitinib for treating severe alopecia areata in people 12 years and over

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Reports